US Stock Insider Trading | Trevi Therapeutics Disclosed 8 Insider Transactions on February 13

K-LinePoet · 2026-03-16T17:41:03+00:00

Trevi Therapeutics recently disclosed 8 insider transactions, primarily consisting of purchases by shareholder Walker Paul Edward, who holds over 10% of the company's shares, acquiring 1.8519 million shares in 2025. The company focuses on developing Nalbuphine ER to treat serious neurologically-mediated diseases, such as idiopathic pulmonary fibrosis and Parkinson's disease.

K-LinePoet

2026-03-16 17:41:03

Abstract generation in progress

On February 13, 2026, Trevi Therapeutics (TRVI) disclosed eight insider trading transactions. Shareholder Walker Paul Edward, who owns more than 10%, purchased 1.8519 million shares on April 17, 2025.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 13, 2026	Shareholder (>10%)	BASKETT FOREST, Behbahani Ali, Chang Carmen, Florence Anthony A. Jr., Makhzoumi Mohamad, New Enterprise Associates 16, L.P., SANDELL SCOTT D, Walker Paul Edward	April 17, 2025	Buy	14,814,800	1.37	20,296,300
December 3, 2025	Executive	Galletta Christopher	December 2, 2025	Buy	4,225	0.51	2,159
March 26, 2025	Executive	SCIASCIA THOMAS	March 25, 2025	Buy	2,631	1.43	3,762
March 26, 2025	Executive	SCIASCIA THOMAS	March 25, 2025	Sell	2,631	6.60	17,400
March 25, 2025	Director	GOOD JENNIFER L	March 21, 2025	Sell	5,263	6.58	34,600
March 25, 2025	Director	GOOD JENNIFER L	March 21, 2025	Buy	5,263	1.43	7,526
March 12, 2025	Executive	Simon Farrell	March 10, 2025	Buy	63,800	3.91	24,950
March 12, 2025	Executive	Simon Farrell	March 10, 2025	Buy	31,300	0.51	1,600
March 12, 2025	Executive	Simon Farrell	March 10, 2025	Buy	17,500	3.21	56,200
March 12, 2025	Executive	Simon Farrell	March 10, 2025	Sell	77,000	6.73	517,800

[Company Profile]

Trevi Therapeutics, Inc. was incorporated on March 17, 2011, under the laws of Delaware. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing Nalbuphine ER for the treatment of severe neuro-mediated diseases. The company is currently developing Nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced motor fluctuations or LID in Parkinson’s disease patients. These conditions share common pathophysiology mediated by opioid receptors in the central and peripheral nervous systems. Due to Nalbuphine’s mechanism as an opioid receptor modulator, the company believes it may be effective in treating these diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.